CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+18.11%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$514M
AUM Growth
+$169M
(+49%)
Cap. Flow
+$116M
Cap. Flow
% of AUM
22.65%
Top 10 Holdings %
Top 10 Hldgs %
26.88%
Holding
503
New
57
Increased
239
Reduced
90
Closed
78
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.88M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$6.46M |
| 3 |
Gilead Sciences
GILD
|
+$6.38M |
| 4 |
Amgen
AMGN
|
+$6.24M |
| 5 |
Adobe
ADBE
|
+$5.19M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$5.18M |
| 2 |
Analog Devices
ADI
|
+$3.75M |
| 3 |
Amazon
AMZN
|
+$3.48M |
| 4 |
lululemon athletica
LULU
|
+$3.4M |
| 5 |
iQIYI
IQ
|
+$1.91M |
Sector Composition
| 1 | Technology | 34.39% |
| 2 | Healthcare | 30.05% |
| 3 | Consumer Discretionary | 17.55% |
| 4 | Communication Services | 6.11% |
| 5 | Consumer Staples | 4.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INBX
201
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $208K | 0.04% |
5,471
+4,354
| +390% | +$165K |
|
202
Ironwood Pharmaceuticals
IRWD
$184M
| $207K | 0.04% |
18,061
+14,064
| +352% | +$161K |
|
203
Lam Research
LRCX
$133B
| $204K | 0.04% |
2,600
-2,340
| -47% | -$184K |
|
204
Danaher
DHR
$142B
| $202K | 0.04% |
871
-111
| -11% | -$25.7K |
|
205
Mondelez International
MDLZ
$80.1B
| $197K | 0.04% |
2,707
-2,362
| -47% | -$172K |
|
206
Vericel Corp
VCEL
$1.68B
| $197K | 0.04% |
+5,521
| New | +$197K |
|
207
Myriad Genetics
MYGN
$643M
| $196K | 0.04% |
10,253
+8,152
| +388% | +$156K |
|
208
Zoetis
ZTS
$67.3B
| $195K | 0.04% |
986
| – | – |
|
209
Automatic Data Processing
ADP
$121B
| $192K | 0.04% |
821
-714
| -47% | -$167K |
|
210
AbCellera Biologics
ABCL
$1.25B
| $192K | 0.04% |
33,566
+26,143
| +352% | +$149K |
|
211
NovoCure
NVCR
$1.41B
| $185K | 0.04% |
12,363
+9,624
| +351% | +$144K |
|
212
Merus
MRUS
$5.08B
| $184K | 0.04% |
6,681
+5,204
| +352% | +$143K |
|
213
Supernus Pharmaceuticals
SUPN
$2.57B
| $183K | 0.04% |
6,314
+4,913
| +351% | +$142K |
|
214
Pacira BioSciences
PCRX
$1.2B
| $181K | 0.04% |
5,373
+4,188
| +353% | +$141K |
|
|
HSAI
215
Hesai Group
HSAI
$3.79B
| $178K | 0.03% |
+20,000
| New | +$178K |
|
216
Structure Therapeutics
GPCR
$1.2B
| $177K | 0.03% |
4,349
+2,939
| +208% | +$120K |
|
217
Zoom
ZM
$25.5B
| $175K | 0.03% |
2,440
-948
| -28% | -$68.2K |
|
218
Syndax Pharmaceuticals
SNDX
$1.41B
| $174K | 0.03% |
8,058
+6,276
| +352% | +$136K |
|
219
Constellation Brands
STZ
$25.8B
| $172K | 0.03% |
+713
| New | +$172K |
|
220
Ardelyx
ARDX
$1.59B
| $166K | 0.03% |
26,851
+21,259
| +380% | +$132K |
|
|
MORF
221
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $166K | 0.03% |
5,753
+4,515
| +365% | +$130K |
|
222
Kymera Therapeutics
KYMR
$3.09B
| $164K | 0.03% |
6,423
+5,002
| +352% | +$127K |
|
223
Grifois
GRFS
$6.88B
| $163K | 0.03% |
14,111
+10,979
| +351% | +$127K |
|
224
Disc Medicine
IRON
$2.15B
| $161K | 0.03% |
+2,793
| New | +$161K |
|
|
225
lululemon athletica
LULU
$19.9B
| $161K | 0.03% |
315
-6,649
| -95% | -$3.4M |
|